{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.5941Y>C",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "Y",
            "alt": "C",
            "position": "5941"
          },
          "Protein Change": {
            "ref": "Y",
            "alt": "C",
            "position": "1699"
          },
          "Description in input context": "c.5941Y>C (p.Y1699C)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0001724"
  },
  "Experiment Method": [
    {
      "Assay Method": "Enzymatic assay and co-immunoprecipitation",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293 cells",
        "Description": "Human embryonic kidney cells (HEK293) were transfected with LRRK2 constructs."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.5941Y>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "The Y1699C mutation resulted in reduced GTPase activity and altered dimerization patterns."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Number of biological replicates not specified in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Number of technical replicates not specified in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type LRRK2 was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "Number of validation controls not specified in the literature."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "Number of validation controls not specified in the literature."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Not described in the literature."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "GTPase activity levels consistent with wild-type LRRK2 function.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Reduced GTPase activity below 50% of wild-type levels.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes",
        "Description": "Enzymatic assays and co-immunoprecipitation are commonly used for studying LRRK2 function in the context of Parkinson's disease."
      }
    }
  ]
}